Stockreport

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF FILSPARI treatment associated with a clinically meaningful lower risk of kidney failure events over five years compared with irbesartan in DUPLEX-aligned RaDaR cohort [Read more]